Do you order PDL1 and molecular testing for patients with stages I-III NSCLC?When I answered this question about two years ago, I said no, primarily because there was no Level 1 efficacy data to support an improvement in outcomes for these patients. This has since changed... although in some ways, n...

Stage III patients are at a higher risk of recurrence. I consider these patients an "at risk" population and I'd like to have the molecular data and the PD-L1 status determined at the time of diagnosis. Of course, I am talking about stage III patients eligible for tri modality treatment. If they are...

At our site, we perform both PDL1 and molecular testing internally. For the last several years, our thoracic group has had a reflex testing agreement in place with our pathologists to initiate both PDL1 and molecular testing for all patients when pathology is consistent with non-squamous NSCLC, incl...

We perform next generation sequencing and PD-L1 testing on all lung cancer patients regardless of stage or histology.

I do because with some Stage III individuals expressing 50% PD-L1 we can use Keytruda monotherapy if they are ineligible for standard combined modality therapy. I currently test the 'actionable' (ie, treatable) mutations as per NCCN. I'm curious how many people instead routinely order the 50-100+ sh...

For patients who are post operative and are candidates for adjuvant therapy, we will perform PD-L1 testing.